Evidence map›Paper›PMID 29696429›Full record

ArticlePediatric cardiology2018

The Pulmonary Artery in Pediatric Patients with Marfan Syndrome: An Underestimated Aspect of the Disease.

Veronika C Stark, Michael Huemmer, Jakob Olfe, Goetz C Mueller, Rainer Kozlik-Feldmann, Thomas S Mir

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. [Latest advances in the diagnosis and treatment of Marfan syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022
    Review
  6. Marfan syndrome.Nature reviews. Disease primers · 2021
    Review
  7. Article
  8. Article
  9. Marfan syndrome: improved clinical history results in expanded natural history.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Veronika C StarkPediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. ve.stark@uke.de.
Michael HuemmerPediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Jakob OlfePediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Goetz C MuellerPediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Rainer Kozlik-FeldmannPediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Thomas S MirPediatric Cardiology, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aortic root dilatation and its complications are known to be the most important and life limiting features in patients with Marfan syndrome (MFS). Since monitoring of patients, preventive medical and surgical treatments are available nowadays, other MFS pathologies are becoming more relevant for the outcome of the disease. Main pulmonary artery (MPA) dilatation is a cardiac finding, which has not been fully investigated in children. Due to the similarities in tissue composition of the aortic and pulmonary root, MPA dilatation may cause complications and require treatment. In addition, it may be a predictor for severe connective tissue involvement. We retrospectively examined 135 pediatric patients with MFS. 8.1% showed MPA dilatation. MPA dilatation was associated with earlier occurrence of aortic dilatation, mitral valve prolapse, and systemic manifestations of MFS compared with patients without MPA dilatation (p < 0.05). The presence of MPA dilatation was also associated with a higher incidence of ectopia lentis (p < 0.05). Medical treatment was started earlier in MPA dilatation patients than in those without (p < 0.05). We conclude that MPA dilatation is a sign of more severe vascular and connective tissue involvement. Regular examination of the pulmonary artery is essential in MFS to avoid complications. As medical treatment of life threatening MFS events has improved, other features of MFS need to be investigated to improve quality of life.

Indexed as

AdolescentAortaChildDilatation, PathologicEchocardiographyFemaleHumansIncidenceMaleMarfan SyndromePulmonary ArteryQuality of LifeRetrospective StudiesAortic root dilatationMarfan syndromeMedical treatmentPulmonary artery dilatation

Identifiers

PMID29696429
OpenAlexW2801677195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.